A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015

Chahine, Lana M.; Amara, Amy W.; Videnović, Aleksandar

doi:10.1016/j.smrv.2016.08.001

Cited by 272 publications

(264 citation statements)

References 347 publications

(378 reference statements)

Supporting

Mentioning

257

Contrasting

Unclassified

Order By: Relevance

“…Limitations include the subjective evaluation of EDS, without objective confirmation, particularly because objective and subjective EDS outcomes are often disparate in PD 4. However, subjective EDS consistently shows clinically important consequences and reduced quality of life and is a useful research tool for prognostic stratification 4 5.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease

Amara

Chahine

Caspell‐Garcia

et al. 2017

J Neurol Neurosurg Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease

Amara

Chahine

Caspell‐Garcia

et al. 2017

J Neurol Neurosurg Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two well characterized examples are Parkinson’s disease and myotonic dystrophy (43, 44). In many cases, the comorbid medical disorder has already been diagnosed when a patient presents with excessive sleepiness, and the diagnosis of hypersomnia due to a medical disorder is made relatively easily.…”

Section: Differential Diagnosis Of Ihmentioning

confidence: 99%

Idiopathic Hypersomnia

Trotti

2017

Sleep Medicine Clinics

View full text Add to dashboard Cite

Idiopathic hypersomnia (IH) is a chronic neurological disorder that results in daytime sleepiness, frequently accompanied by long nocturnal or daytime sleep, unrefreshing sleep, difficulty in awakening, cognitive dysfunction, and autonomic symptoms. The cause of idiopathic hypersomnia is presently unknown, although a genetic predisposition is suggested by the strong family history of similar symptoms. Dysfunction of autonomic, inflammatory, or immune systems has been proposed, and patients with IH have been found to have an endogenous modulator of GABA-A receptors within their cerebrospinal fluid. Diagnosis of IH involves a careful clinical history, with particular attention to the possibility of other disorders with similar symptomatology, and objective testing with actigraphy, polysomnography, and multiple sleep latency testing. There are no FDA-approved treatments for IH symptoms, which are typically treated with off-label use of medications approved for narcolepsy. Modafinil is first line and supported by two randomized, controlled trials in IH patients. A substantial fraction of IH patients are refractory or intolerant to standard treatments, and different treatment strategies, employing novel therapeutics, are necessary in these cases. Even with current treatment options, quality of life and safety may remain impaired in patients with this challenging chronic disease.

show abstract

“…In PD patients, sleep disorders include insomnia, vivid dreams, restless legs syndrome (RLS), rapid eye movement sleep behavior disorder (RBD), periodic limb movements (PLM), circadian rhythm disruption and excessive daytime sleepiness (EDS) [10]. The etiology of sleep disorders in PD are likely to be multifactorial.…”

Section: Introductionmentioning

confidence: 99%

Poor nighttime sleep is positively associated with dyskinesia in Parkinson's disease patients

Mao

Yang

Chen

et al. 2018

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Background Dyskinesia is a troublesome complication of long-term dopaminergic medications in Par-kinson’s disease (PD) patients. Many factors are reported to be associated with dyskinesia in PD. Objective To investigate the association between sleep quality and dyskinesia in patients with PD. Methods Four hundred twenty-five patients with PD were enrolled in this study. Demographic information was collected. Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr (H-Y) stage scale were also performed. Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI) were applied to evaluate daytime sleepiness and overall nighttime sleep quality, respectively, in PD patients. Results Patients with dyskinesia tended to have a longer duration of disease, higher daily levodopa-equivalent dose (LED), H-Y stage, UPDRS II and PSQI score, and a higher percentage of levodopa treatment than those without dyskinesia. After adjusting for age, sex, age at onset of PD, disease duration, UPDRS I, UPDRS II, UPDRS III, cigarette smoking, use of different antiparkinsonian drugs, phenotype, daily LED, and restless leg syndrome (RLS), PSQI score was still associated with dyskinesia, with corresponding ORs 1.111 (95% CI, 1.004–1.229) as a continuous variable, and 2.469 (95% CI, 1.051–5.800) as a categorical variable, respectively. Further analysis of PSQI components showed that subjective sleep quality and sleep latency were associated with dyskinesia in PD patients. Conclusions Our data showed that poor nighttime sleep is positively associated with dyskinesia in PD patients. Attention to the management of nighttime sleep quality may be beneficial to dyskinesia in patients with PD.

show abstract

A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015

Cited by 272 publications

References 347 publications

Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease

Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease

Idiopathic Hypersomnia

Poor nighttime sleep is positively associated with dyskinesia in Parkinson's disease patients

Contact Info

Product

Resources

About